March 16, 2025  Home  |  About Us  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages  |  Contact Us  |  中文
HeBei Med  2017, Vol. 23 Issue (11): 1905-1908    DOI: 10.3969/j.issn.1006-6233.2017.11.043
Current Issue | Archive | Adv Search |
Clinical Observation of Shengxuening Tablets in the Treatment of Maintenance Hemodialysis Patients with Renal Anemia
MA Xiaohui
Chengde County Hospital, Hebei Chengde 067000, China
Download: PDF (1374 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  Objective: To observe the clinical efficacy of Shengxuening tablets to improve the law to maintain iron metabolism in hemodialysis patients with renal anemia and erythropoietin and its synergistic effect. Methods: 60 cases uremic patients with renal anemia selected as the research object, randomly divided into Shengxuening group and succinic acid ferrous group, 30 cases in each group. The patients of shengxuening group were given oral Shengxuening tablets, and oral ferrous succinate group was given Ferrous Succinate Tablets. In accordance with the guidelines, the patients of 2 groups were given the recommended dose individualized combination of erythropoietin treatment. After 16-weeks treatment, the clinical curative effect of the patients of 2 groups were observed and the changes of hemoglobin, hematocrit, serum ferritin and transferrin saturation were recorded before and after treatment in 2 groups. Meanwhile, the adverse reactions in the 2 groups were monitored. Results: After 16 weeks of treatment, the hemoglobin, hematocrit, serum ferritin, transferrin saturation of the 2 groups were increased compared with before treatment, the difference was statistically significant (P < 0.05). However, after treatment, the hemoglobin, hematocrit, serum ferritin, transferrin saturation of Shengxuening group was significantly higher than that of ferrous succinate group, the difference was statistically significant (P < 0.05). Compared with ferrous succinate group, Shengxuening group of adverse reaction is less. Conclusion: Compared with ferrous succinate group, Shengxuening can effectively supplement renal anemia in patients with uremia for iron, and less adverse reactions of blood safety.
Key wordsShengxuening      Renal anemia      Hemodialysis     
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Cite this article:   
URL:  
http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.11.043     OR     http://www.hbyxzzs.cn/EN/Y2017/V23/I11/1905
Copyright © Editorial Board of HeBei Med
Supported by:Beijing Magtech